The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- Propofol therapeutic outcomes
研究概览
简要总结
This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia. Despite propofol's fast onset and favorable recovery profile, significant inter-individual variability exists in its dosing requirements, sedation depth, and adverse effects. Such variability is believed to arise in part from genetic differences that affect drug metabolism and action. This research focuses on identifying how specific gene variants, particularly those linked to poor or altered metabolizer phenotypes, influence clinical outcomes like induction time, recovery time, and safety profiles during anesthesia.
详细描述
Focusing on the Pakistani population, this research seeks to fill a gap in regional pharmacogenetic data, which is limited but critical for optimizing patient care. By identifying associations between genetic profiles and anesthetic responses, the findings could support the development of personalized anesthesia protocols, improving drug safety and effectiveness. This project has great potential to advance precision medicine in anesthesiology by enabling more personalized therapeutic strategies that are guided by each patient's distinct genetic makeup.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female & males aged 18-60yrs
- •ASA grade 1 & II
- •Patient enrolled for elective surgery
排除标准
- •History of drug allergies
- •Any chronic disease such as hepatic, psychiatric & kidney disease.
- •History of drug intake (opioids, analgesics)
- •History of smoking, alcohol or drug addiction.
研究组 & 干预措施
Isoflurane Group
干预措施: Isoflurane Group (Combination Product)
Propofol Group
干预措施: Propofol Group (Diagnostic Test)
结局指标
主要结局
Propofol therapeutic outcomes
时间窗: 24 Months
Produces prompt hypnosis (within 40 seconds) and allows for rapid awakening upon discontinuation (10-30 min)
次要结局
未报告次要终点
研究者
Muhammad Naveed Babur
Principal Investigator
Superior University